{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:05:12Z","timestamp":1784232312219,"version":"3.55.0"},"reference-count":10,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"unspecified","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["NSFC-82173385"],"award-info":[{"award-number":["NSFC-82173385"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,2,20]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>This research analyzes the global landscape of clinical trials focusing on therapies targeting the Nectin cell adhesion molecule 4 (Nectin-4) across various malignancies, using data from the Trialtrove database. Analysis of 136 interventional trials reveals a rapidly expanding field dominated by antibody-drug conjugates, particularly in urothelial carcinoma, with significant activity in combination regimens and diverse therapeutic modalities under exploration. These findings emphasize the substantial translational potential of Nectin-4 and highlight key trends shaping its future clinical development.<\/jats:p>","DOI":"10.1136\/jitc-2025-014345","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:23:37Z","timestamp":1773156217000},"page":"e014345","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical application prospects of Nectin-4 in pan-cancer: an analysis based on the Trialtrove database"],"prefix":"10.1136","volume":"14","author":[{"given":"Lei","family":"Li","sequence":"first","affiliation":[{"name":"Department of Urology, Peking University Third Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Hernia and Abdominal Wall Surgery, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University Third Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University Third Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University Third Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoliang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University Third Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shudong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University Third Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2141-9348","authenticated-orcid":false,"given":"Lulin","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University Third Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"2026031008101560000_14.3.e014345.1","doi-asserted-by":"crossref","first-page":"174516","DOI":"10.1016\/j.ejphar.2021.174516","article-title":"Nectin cell adhesion molecule-4 (NECTIN-4): A potential target for cancer therapy","volume":"911","author":"Chatterjee","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"2026031008101560000_14.3.e014345.2","doi-asserted-by":"crossref","first-page":"7391","DOI":"10.1097\/JS9.0000000000002770","article-title":"Overcoming the quality gap in clinical trial landscape analysis: Paving the way for impactful research","volume":"111","author":"Wang","year":"2025","journal-title":"Int J Surg"},{"key":"2026031008101560000_14.3.e014345.3","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70479","article-title":"Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience","volume":"14","author":"Rizzo","year":"2025","journal-title":"Cancer Med"},{"key":"2026031008101560000_14.3.e014345.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102278"},{"key":"2026031008101560000_14.3.e014345.5","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.1158\/1078-0432.CCR-24-1393","article-title":"FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma","volume":"30","author":"Brave","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026031008101560000_14.3.e014345.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117"},{"key":"2026031008101560000_14.3.e014345.7","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18572","article-title":"Exploring membranous NECTIN-4 expression patterns and enfortumab vedotin response in prostate cancer","volume":"28","author":"Weiten","year":"2024","journal-title":"J Cell Mol Med"},{"key":"2026031008101560000_14.3.e014345.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268387"},{"key":"2026031008101560000_14.3.e014345.9","doi-asserted-by":"crossref","first-page":"100781","DOI":"10.1016\/j.modpat.2025.100781","article-title":"Evaluation of Nectin-4 and Trop-2: Implications for Patient Outcomes and Therapy in Penile Cancer","volume":"38","author":"Mink","year":"2025","journal-title":"Mod Pathol"},{"key":"2026031008101560000_14.3.e014345.10","doi-asserted-by":"crossref","unstructured":"Ricci C , Di Sciascio L , Ambrosi F , et al . New insights into Nectin-4 expression in testicular choriocarcinoma and its potential treatment with Enfortumab Vedotin: analysis of a multi-institutional series and association with clinical-pathological features. Virchows Arch 2026. doi:10.1007\/s00428-026-04416-2","DOI":"10.1007\/s00428-026-04416-2"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:23:39Z","timestamp":1773156219000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":10,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,10]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/jitc-2025-014345"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014345","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}